Focus on Multi-targeted Role of Curcumin: a Boon in Therapeutic Paradigm.
Aromatherapy
Cancer
Combination therapy
Curcumin
Multi-target
Therapeutics
Journal
Environmental science and pollution research international
ISSN: 1614-7499
Titre abrégé: Environ Sci Pollut Res Int
Pays: Germany
ID NLM: 9441769
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
22
05
2020
accepted:
01
02
2021
pubmed:
18
2
2021
medline:
10
4
2021
entrez:
17
2
2021
Statut:
ppublish
Résumé
Curcumin is a polyphenolic compound that exhibited good anticancer potential against different types of cancers through its multi-targeted effect like the termination of cell proliferation, inflammation, angiogenesis, and metastasis, thereby acting as antiproliferative and cytotoxic in nature. The present review surveys the various drug combination tried with curcumin or its synthetic analogues and also the mechanism by which curcumin potentiates the effect of almost every drug. In addition, this article also focuses on aromatherapy which is gaining much popularity in cancer patients. After thoroughly studying several articles on combination therapy of curcumin through authenticated book chapters, websites, research, and review articles available at PubMed, ScienceDirect, etc., it has been observed that multi-targeted curcumin possess enormous anticancer potential and, with whatever drug it is given in combination, has always resulted in enhanced effect with reduced dose as well as side effects. It is also capable enough in overcoming the problem of chemoresistance. Besides this, aromatherapy also proved its potency in reducing cancer-related side effects. Combining all the factors together, we can conclude that combination therapy of drugs with curcumin should be explored extensively. In addition, aromatherapy can be used as an adjuvant or supplementary therapy to reduce the cancer complications in patients.
Identifiants
pubmed: 33595796
doi: 10.1007/s11356-021-12809-w
pii: 10.1007/s11356-021-12809-w
doi:
Substances chimiques
Antineoplastic Agents
0
Curcumin
IT942ZTH98
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
18893-18907Références
Abdalla MO, Karna P, Sajja HK, Mao H, Yates C, Turner T, Aneja R (2011) Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release 149(3):314–322
Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles FR, Snyder JP, Liotta DC, Shoji M (2004) Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem Lett 12(14):3871–3883
Aggarwal BB (2000) Apoptosis and transcription factor NF-kappa B: a tale of association and dissociation. BiochemPharmacol 60:1033–1039
Aggarwal BB, Sung B (2008) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Cell Press 30(2):85–94
Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23:363–398
Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB (2006) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of I kappa B alpha kinase and Akt activation. Mol Pharmacol 69:195–106
Agrawal V, Maharjan S, Kim K et al (2014) Direct endothelial junction restoration results in significant tumor vascular normalization and metastasis inhibition in mice. Oncotarget 5:2761–2777
Albasher G, Abdel-Daim MM, Almeer R, Ibrahim KA, Hamza RZ, Bungau S, Aleya L (2019) Synergistic antioxidant effects of resveratrol and curcumin against fipronil-triggered oxidative damage in male albino rats. Environ. Sci Pollut Res 27:6505–6514
Almasi CE, Drivsholm L, Pappot H, Høyer-Hansen G, Christensen IJ (2013) The liberated domain I of urokinase plasminogen activator receptor–a new tumour marker in small cell lung cancer. APMIS 121(3):189–196
Ammon HP, Safayhi H, Mack T, Sabieraj J (1993) Mechanism of anti-inflammatory actions of curcumin and boswellic acids. J Ethnopharmacol 38:113–119
Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB (2008) Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett 267:133–164
Anuchapreeda S, Tima S, DuangratC LP (2008) Effect of pure curcumin, demethoxycurcumin, and bisdemethoxycurcumin on WT1 gene expression in leukemic cell lines. Cancer Chemother Pharmacol 62:585–594
Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, Bergamo F, Cortinovis D, Cazzaniga M, Santos C, Papadimitriou K, Kalofonos HP (2013) Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119(2):438–444
Astsaturov I, Cohen RB, Harari PM (2006) EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 6(8):691–700
Astsaturov I, Cohen RB, Harari P (2007) EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 7(7):650–665
Banerjee M, Singh P, Panda D (2010) Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF-7 cells. FEBS J 277:3437–3448
Beijers AJ, Mols F, Vreugdenhil GA (2014) Systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 22(7):1999–2007
Bharti AC, Donato N, Aggarwal BB (1993) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171:3863–3887
Bharti AC, Donato N, Singh S, Aggarwal BB (2003) Curcumin downregulates the constitutive activation of NF-kappa B and I Kappa B alpha kinase in human multiple myeloma cells leading to suppression of proliferation and induction of apoptosis. Blood 101(3):1053–1062
Bhaumik S, Anjum R, Rangaraj N, Pardhasaradhi BV, Khar A (1999) Curcumin mediated apoptosis in AK-5 tumour cells involves the production of reactive oxygen intermediates. FEBS Lett 456:311–314
Bhavani Shankar TN, Sreenivasan MV (1979) Effect of turmeric (Curcuma longa) fractions on the growth of some intestinal and pathogenic bacteria in vitro. Indian J Exp Biol 17:1363–1366
Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Müller M, Mackman N, Ziegler R, Nawroth PP (1997) The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-κB. Thromb Haemost 77:772–782
Borges GÁ (2017) In vivo and in vitro effects of curcumin on head and neck carcinoma: a systematic review. J Oral Pathol Med 46:3–20
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–324
Brouet I, Ohshima H (1995) Curcumin, an antitumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 206:533–540
Brozovic A (2017) The relationship between platinum drug resistance and epithelial-mesenchymal transition. Arch Toxicol 91:605–619
Buckle J (2002) Clinical aromatherapy and AIDS. J Assoc Nurses AIDS Care 13(3):81–99
Caldow Pilgrim CH, Groeschl RT, Quebbeman EJ, Aliberti C, Fiorentini G (2013) Recent advances in systemic therapies and radiotherapy for gallbladder cancer. Surg Oncol l22(1):61–67
Carlsson L, Bratman SV, Siu LL, Spreafico A (2017) The cisplatin total dose and concomitant radiation in locoregionally advanced head and neck cancer: Any recent evidence for dose efficacy? Curr Treat Options in Oncol 18:39
Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10:417–427
Cassell A, Grandis JR (2010) Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs 19:709–722
Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410:37–40
Chattopadhyay I, Kaushik B, Bandyopadhyay U, Banerjee RK (2004) Turmeric and curcumin: biological actions and medicinal applications. Curr Sci 87(1):44–53
Chau I, Webb A, Cunningham D, Hill M, Rao S, Ageli S, Norman A, Gill K, Howard A, Catovsky D (2001) An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 115(4):786–792
Chen YC, Kuo TC, Lin-Shiau SY, Lin JK (1996) Induction of HSP70 gene expression by modulation of Ca (+2) ion and cellular p53 protein by curcumin in colorectal carcinoma cells. Mol Carcinog 17:224–234
Chen X, Hasuma T, Yano Y, Yoshimata T, Morishima Y, Wang Y, Otani S (1997) Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin. Anticancer Res 17:2555–2564
Chen CF, Lu CC, Chiang JH, Chiu HY, Yang JS, Lee CY, Way TD, Huang HJ (2018) Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin resistant oral cancer CAR cells through intrinsic apoptotic process. Oncol Lett 16(5):6323–6330
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27–55
Choudhuri T, Pal S, Aggarwal ML, Das T, Sa G (2002) Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 512:334–340
Chun KS, Surh YJ (2004) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 68:1089–1100
Clark DL, Boutros NN (1999) The brain and behaviour. In: An introduction to behavioural neuroanatomy. Blackwell Science, Oxford
Cruz-Correa M, Shoskes DA, Sanchez P et al (2006) Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clinic. Gastroenterol Hepatol Offic Clinic Pract J Am Gastroenterol Assoc 4:1035–1038
Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378
Degardin M, Cappelaere P, Krakowski I et al (1996) Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 32b(4):278–279
Del Curatolo A, Conciatori F, CestaIncani U et al (2018) Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumour models. J Exp Clin Cancer Res 37:140
Deodhar SD, Sethi R, Srimal RC (1980) Preliminary study on antirheumatic activity of curcumin (diferuloylmethane). Indian J Med Res 71:632–634
Faião-Flores F, Suarez JAQ, Pardi PC, Maria DA (2012) DM-1, sodium 4-(5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl)-2-methoxy-phenolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment. Tumour Biol 33:775–785
Fang J, Lu J, Holmgren A (2005) Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 280:25284–25290
Farahani MA, Afsargharehbagh R, Marandi F, Moradi M, Hashemi SM, Moghadam MP, Balouchi A (2019) Effect of aromatherapy on cancer complications: a systematic review. Compl Ther Med 47:102169
Fellowes D, Barnes K, Wilkinson S (2004) Aromatherapy and massage for symptom relief in patients with cancer. Cochrane Datab Syst Rev (3):CD002287.pub2. https://doi.org/10.1002/14651858.CD002287
Fetoni AR, Paciello F, Mezzogori D, Rolesi R, Eramo SLM, Paludetti G, Troiani D (2015) Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. Br J Cancer 113:1434–1444
Fratantonio D, Molonia SM, Bashllari R et al (2019) Curcumin potentiates the antitumour activity of Paclitaxel in rat glioma C6 cells. Phytomedicine 55:23–30
Geda A (1995) Antibacterial activity of essential oils and their combinations. Fat Sci Tech 97:458–460
Ghosh AK, Kay NE, Secreto CR, Shanafelt TD (2009) Curcumin inhibits pro-survival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res 15:1250–1258
Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23–30
Gomes Dde C, Alegrio LV, de Lima ME, Leon LL, Araújo CA (2002) Synthetic derivatives of curcumin and their activity against Leishmania amazonensis. Arzneimittel Schung 52:120–124
Hanazawa S, Takeshita A, Amano S, Semba T, Nirazuka T, Katoh H, Kitano S (1993) Tumour necrosis factor-alpha induces expression of monocyte chemoattractant JE via fos and jun genes in clonal osteoblastic MC3T3-E1 cells. J Biol Chem 268:9526–9532
He M, Li Y, Zhang L et al (2014) Curcumin suppresses cell proliferation through inhibition of the Wnt/beta-catenin signalling pathway in medulloblastoma. Oncol Rep 32:173–180
Hong Y, She S, Hui B et al (2019) Lung cancer therapy using doxorubicin and curcumin combination: targeted prodrug based, pH sensitive nanomedicine. Biomed Pharmacother 112:108614
Horn D, Hess J, Freier K, Hoffmann J, Freudlsperger C (2015) Targeting EGFR-PI3K-AKT-mTOR signalling enhances radiosensitivity in head and neck squamous cell carcinoma. Expert Opin Ther Targets 19:795–705
Hossain M, Banik NL, Ray SK (2012) Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int 61:1102–1113
Howells LM, Mitra A, Manson MM (2007) Comparison of oxaliplatin and curcumin-mediated antiproliferative effects in colorectal cell lines. Int J Oncol 121(1):175–183 http://cancerindia.org.in/cancer-treatment-centers/ , updated on march 2, 2020
Hurtado M, Sankpal UT, Ranjan A, Maram R, Vishwanatha JK, Nagaraju GP, el-Rayes BF, Basha R (2018) Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. Crit Rev Oncol Hematol 126:201–207
Hwang H, Jeong HS, Oh PS, Kim M, Lee TK, Kwon JI, Kim HS, Lim ST, Sohn MH, Jeong HJ (2016) PEGylated nanoliposomes encapsulating angiogenic peptides improve perfusion defects: radionuclide imaging-based study. Nucl Med Biol 43(9):552–558
Ibrahim A, Hirschfeld SA, Cohen MH, Griebel DJ, Williams GA, Pazdur R (2004) FDA drug approval summaries: oxaliplatin. Oncologist 9(1):8–12
India Against Cancer (2020). Cancer treatment centers. Retrieved from India against cancer website https://www.cancerindia.org.in/cancer-treatment-centers .
India Today (2018). Cancer rate doubles in India: facts, stats, cure and treatment of the most deadly disease in the world. Retrieved from India Today Web Desk website https://www.indiatoday.in/education-today/gk-current-affairs/story/cancer-rate-india-stats-cure-treatment-1386739-2018-11-12 .
Innamaa A, Jackson L, Asher V et al (2013) Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer. Clin Transl Oncol 15:910–918
Irving GRB, Iwuji COO, Morgan B, Berry DP, Steward WP, Thomas A, Brown K, Howells LM (2015) Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. Trials 16(1):110
Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J, Sachinidis A (2009) Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr Med Chem 16:1451–1462
Jain RK (2005) Normalization of tumour vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62
Jaiswal S, Mishra P (2018) Co-delivery of curcumin and serratiopeptidase in HeLa and MCF-7 cells through nanoparticles show improved anti-cancer activity. Mater 92:673–684
James MI, Iwuji C, Irving G et al (2015) Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Lett 364(2):135–141
Jardim DL, Rodrigues CA, Novis YA, Rocha VG, Hoff PM (2012) Oxaliplatin-related thrombocytopenia. Ann Oncol 23(8):1937–1942
Ji JL, Huang XF, Zhu HL (2012) Curcumin and its formulations: potential anti-cancer agents. Anti Cancer Agents Med Chem 12:210–218
Jobin C, Bradham CA, Russo MP (1999) Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa-B-kinase activity. J Immunol 163:3474–3483
Jong NN, Nakanishi T, Liu JJ, Tamai I, McKeage MJ (2011) Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. Aust J Pharm 338(2):537–547
Kaessmeyer S, Bhoola K, Baltic S, Thompson P, Plendl J (2014) Lung cancer neovascularisation: cellular and molecular interaction between endothelial and lung cancer cells. Immunobiology 219:308–314
Kakar SS, Roy D (1994) Curcumin inhibits TPA induced expression of c-fos, c-jun and c-myc proto-oncogenes messenger RNAs in mouse skin. Cancer Lett 87:85–89
Kamal-Eldin A, Frank J, Razdan A, Tengblad S, Basu S, Vessby B (2000) Effects of dietary phenolic compounds on tocopherol, cholesterol, and fatty acids in rats. Lipids 35:427–435
Kamat AM, Sethi G, Aggarwal BB (2007) Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappa B and nuclear factor-kappa B-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther 6:1022–1030
Kamata T (2009) Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci 100:1382–1388
Kanwar SS, Yu Y, Nautiyal J, Patel BB, Padhye S, Sarkar FH, Majumdar APN (2011) Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 28(4):827–838
Kaustubh AG, Sau S, Tatiparti K et al (2018) Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. Colloids Surf B 167:8–19
Kelkel M, Jacob C, Dicato M, Diederich M (2014) Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies. Molecules 15(10):7035–7074
Khar A, Ali AM, Pardhasaradhi BV, Begum Z, Anjum R (1999) Antitumour activity of curcumin is mediated through the induction of apoptosis in AK-5 tumour cells. FEBS Lett 445:165–168
Kim MS, Kang HJ, Moon A (2001a) Inhibition of invasion and induction of apoptosis by curcumin in H-ras-transformed MCF10A human breast epithelial cells. Arch Pharm Res 271:305–314
Kim MS, Kang HJ, Moon A (2001b) Inhibition of invasion and induction of apoptosis by curcumin in H-ras-transformed MCF10A human breast epithelial cells. Arch Pharm Res 24:349–354
Kim JM, Noh EM, Kwon KB, Kim JS, You YO, Hwang JK, Hwang BM, Kim BS, Lee SH, Lee SJ, Jung SH, Youn HJ, Lee YR (2012) Curcumin suppresses the TPA-induced invasion through inhibition of PKCα-dependent MMP-expression in MCF-7 human breast cancer cells. Phytomedicine 19:1085–1092
Köberle B, Tomicic MT, Usanova S, Kaina B (2010) Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 1806:172–182
Koide T, Nose M, Ogihara Y, Yabu Y, Ohta N (2002) Leishmanicidal effect of curcumin in vitro. Biol Pharm Bull 25:131–133
Komori T, Fujiwara R, Tanida M, Nomura J, Yokoyama MM (1995) Effects of citrus fragrance on immune function and depressive states. Neuroimmunomodulation 2:174–180
Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signalling proteins. Cancer Lett 269(2):199–125
Kunwar A, Barik A, Maishra B et al (2008) Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumour cells. Biochim Biophys Acta 1780:673–679
Kuo ML, Huang TS, Lin JK (1996) Curcumin, an antioxidant and anti-tumour promoter, induces apoptosis in human leukemia cells. Biochem Biophys Acta 1317:95–100
Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, Nakamura I, Han T, Aderca I, Isomoto H, Garrity-Park MM, Shire AM, Li J, Sanderson SO, Adjei AA, Fernandez-Zapico ME, Roberts LR (2010) The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. J Hepatol 52:1680–1689
Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, Thomas RR, Grem JL (2005) Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 5:116
Liacini A, Sylvester J, Li WQ, Zafarullah M (2002) Inhibition of interleukin- 1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 21:251–262
Liebig H, Günther G, Kolb M, Mozet C, Boehm A, Dietz A, Wichmann G (2017) Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways. Cancer Chemother Pharmacol 79:411–420
Lin JK (2007) Molecular targets of curcumin. Adv Exp Med Biol 595:227–243
Lin MC, Huang MJ, Liu C, Yang TL, Huang MC (2014) GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity. Oral Oncol 50:478–484
Liu S, Wang Z, Hu Z, Zeng X, Li Y, Su Y, Zhang C, Ye Z (2011) Anti-tumour activity of curcumin against androgen-independent prostate cancer cells via inhibition of NF-κB and AP-1 pathway in vitro. J Huazhong Univ Sci TechnolMed Sci 31:530–534
Liu Z, Tang L, Zou P, Zhang Y, Wang Z, Fang Q, Jiang L, Chen G, Xu Z, Zhang H, Liang G (2014) Synthesis and biological evaluation of allylated and prenylated mono-carbonyl analogs of curcumin as anti-inflammatory agents. Eur J Med Chem 74:671–682
Liu B, Han L, Liu J, Han S, Chen Z, Jiang L (2017) Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumour activity against cervical cancer. Int J Nanomedicine 12:955–968
Liu Q, Loo WTY, Sze SCW, Tong Y (2019) Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation ofNFκB, cyclin D and MMP-1 transcription. Phytomedicine 16:916–922
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A, GERCOR, GISCAD (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. Am J Clin Oncol 23(15):3509–3516
Lu YP, Chang RL, Lou YR, Huang MT, Newmark HL, Reuhl KR, Conney AH (1994) Effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate- and ultraviolet B light-induced expression of c-Jun and c-Fos in J136 cells and in mouse epidermis. Carcinogenesis 15:2363–2370
Luo J, Qu J, Yang R et al (2016) Phytochemicals mediate the expression and activity of OCTN2 as activators of the PPARγ/RXRα pathway. Front Pharmacol 7:189
Ma Y, Fan X, Li L (2016) pH-sensitive polymeric micelles formed by doxorubicin conjugated prodrugs for co-delivery of doxorubicin and paclitaxel. CarbohydrPolym 137:19–29
Mahady GB, Pendland SL, Yun G, Lu ZZ (2002) Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, of group 1 carcinogen. Anticancer Res 22:4179–4181
Manning BD, Cantley LC (2007) AKT/PKB signalling: navigating downstream. Cell 129:1261–1274
Manolova Y, Deneva V, Antonov L et al (2014) The effect of the water on the curcumin tautomerism: a quantitative approach. Spectrochim Acta A 132:815–820
Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33:369–385
Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31(21):2699–2707
Momtazi AA, Sahebkar A (2016) Difluorinated curcumin: a promising curcumin analogue with improved anti-tumour activity and pharmacokinetic profile. Curr Pharm Des 22(28):4386–4397
Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G (2011) Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer 14(1):50–55
Moon C, Chae YK, Lee J (2010) Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp Biol Med (Maywood) 235:907–920
Moragoda L, Jaszewski R, Majumdar AP (2001) Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res 21:873–878
Nagai H, Kim YH (2017) Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis 9(3):448–451
Nagaraju GP, Benton L, Bethi SR, Shoji M, El-Rayes BF (2019) Curcumin analogs: their roles in pancreatic cancer growth and metastasis. Int J Cancer 145(1):10–19
Ni W, Li Z, Liu Z et al (2018) Dual-targeting nanoparticles: codelivery of curcumin and 5-fluorouracil for synergistic treatment of hepatocarcinoma. J Pharm Sci XXX:1–12
Nirmala C, Puvanakrishnan R (1996) Protective role of curcumin against isoproterenol-induced myocardial infarction in rats. Mol Cell Biochem 159:85–93
Njiaju UO, Tevaarwerk AJ, Kim K, Chang JE, Hansen RM, Champeny TL, Traynor AM, Meadows S, van Ummersen L, Powers K, Stewart JA (2013) Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial. Cancer Chemother 71(3):613–618
Olivera A, Moore TW, Hu F, Brown AP, Sun A, Liotta DC, Snyder JP, Yoon Y, Shim H, Marcus AI, Miller AH, Pace TWW (2012) Inhibition of the NF-kappa B signalling pathway by the curcumin analog, 3,5-bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int Immunopharmacol 12(2):368–377
Onen HI, Yilmaz A, Alp E, Celik A, Demiroz SM, Konac E, Kurul IC, Menevse ES (2015) EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells. Hum Exp Toxicol 34(2):117–126
Ozerdem U, Stallcup WB (2004) Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis 7:269–276
Padhye S, Yang H, Jamadar A, Cui QC, Chavan D, Dominiak K, McKinney J, Banerjee S, Dou QP, Sarkar FH (2009) New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res 26(8):1874–1880
Pan MH, Lin-Shiau SY, Lin JK (2000) Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through downregulation of I kappa B kinase and NF kappa B activation in macrophages. Biochem Pharmacol 60:1665–1676
Pan MH, Chang WL, Lin-Shiau SY, Ho CT, Lin JK (2001) Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells. J Agric Food Chem 49:1464–1474
Park DC, Yeo SG, Shin EY et al (2006) Clusterin confers paclitaxel resistance in cervical cancer. Gynecol Oncol 103:996–1000
Patel BB, Sengupta R, Qazi S et al (2008) Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Oncol 122(2):267–273
Pectasides D, Pectasides M, Farmakis D, Gaglia A, Koumarianou A, Nikolaou M, Koumpou M, Kountourakis P, Papaxoinis G, Mitrou P, Economopoulos T, Raptis SA (2004) Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol 95(1):165–172
Piwocka K, Jaruga E, Skierski J, Gradzka I, Sikora E (2001) Effect of glutathione depletion on caspase-3 independent apoptosis pathway induced by curcumin in Jurkat cells. Free Radic Biol Med 31:670–678
Plas DR, Thompson CB (2005) Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24:7435–7442
Plummer SM, Holloway KA, Manson MM, Munks RJL, Kaptein A, Farrow S, Howells L (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappa B activation via the NIK/IKK signalling complex. Oncogene 18:6013–6020
Polsky D, Cordon-Cardo C (2003) Oncogenes in melanoma. Oncogene 22:3087–3091
Prasad CP, Rath G, Mathur S, Limtrakul P (2009) Potent growth suppressive activity of curcumin in human breast cancer cells: modulation of Wnt/beta-catenin signalling. Chem Biol Interact 181:263–271
Prince A, Aguirre-Ghizo J, Genden E, Posner M, Sikora A (2010) Head and neck squamous cell carcinoma: New translational therapies. Mt Sinai J Med 77:684–699
Psyrri A, Seiwert TY, Jimeno A (2013) Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am Soc Clin Oncol Educ Book:246–255
Punithavathi D, Venkatesan N, Babu M (2000) Curcumin inhibition of bleomycin induced pulmonary fibrosis in rats. Br J Pharmacol 131:169–172
Qadir MI, Naqvi STQ, Muhammad SA (2016) Curcumin: a polyphenol with molecular targets for cancer control. Asian Pac J Cancer Prev 17(6):2735–2739
Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y (2013) Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 31(28):3501–3508
Raana F, Younes PS, Dadashpour M et al (2017) Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells, artificial cells. Artif Cells Nanomed Biotechnol:917–925
Rajitha B, Nagaraju GP, Shaib WL et al (2017) Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer. Mol Carcinog 56(1):288–299
Ramachandran C, Fonseca HB, Jhabvala P, Melnick SJ (2002) Curcumin inhibits telomerase activity through humantelomerase reverse transcritpase in MCF-7 breast cancer cell line. Cancer Lett 184:1–6
Rithaporn T, Monga M, Rajasekharan M (2003) Curcumin a potential vaginal contraceptive. Contraception 68:219–223
Roebuck KA (1999) Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF kappa B. Int J Mol Med 4:223–230
Rosin MP, Saad-el-Din ZS, Ward AJ, Anwar WA (1994) Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients. Mutat Res 305:283–292
Ruiz De Porras V, Bystrup S, Martínez-Cardús A et al (2016) Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway. Sci Rep 6:24675
Sajithlal GB, Chittra P, Chandrakasan G (1998) Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. BiochemPharmacol 56:1607–1614
Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O'Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J, Kayitalire L, Crino L, Paz-Ares L (2005) Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 11(2 Pt 1):690–696
Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, Zayed M, Alharbi S, Tan B, Kumar A, Sethi G (2015) The multifaceted role of curcumin in cancer prevention and treatment. Molecules 20:2728–2769
Shehzad A, Wahid F, Lee YS (2010) Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 343:489–499
Shetty D, Kim YJ, Shim H, Snyder JP (2014) Eliminating the heart from the curcumin molecule: monocarbonyl curcumin mimics (MACs). Molecules (Basel, Switzerland) 20(1):249–292
Shiina Y, Funabashi N, Lee K, Toyoda T, Sekine T, Honjo S, Hasegawa R, Kawata T, Wakatsuki Y, Hayashi S, Murakami S, Koike K, Daimon M, Komuro I (2008) Relaxation effects of lavender aromatherapy improve coronary flow velocity reserve in healthy men evaluated by transthoracic Doppler echocardiography. Int J Cardiol 129(2):193–197
Shishodia S, Aggarwal BB (2002) Nuclear factor-kappa B activation: a question of life and death. J Biochem Mol Biol 35:28–40
Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 96:5522–5527
Shukla Y, Arora A (2003) Suppression of altered hepatic foci development by curcumin in Wistar rats. Nutr Cancer 45:53–59
Siegel RL, Miller KD, Jemal A (2019) Cancer statistics. CA Cancer J Clin 69(1):7–34
Srihari Rao T, Basu N, Siddqui HH (1982) Anti-inflammatory activity of curcumin analogues. Indian J Med Res 75:574–578
Srimal, RC, Dhawan BN (1985) In: B.B. Arora (Ed.), Development of unani drugs from herbal sources and the role of elements in their mechanism of action. Hamdard National Foundation Monograph, New Delhi. India
Srivastava NS, Srivastava RAK (2019) Curcumin and quercetin synergistically inhibit cancer cell proliferation in multiple cancer cells and modulate Wnt/β-catenin signalling and apoptotic pathways in A375 cells. Phytomedicine 52:117–128
Srivastava R, Dikshit M, Srimal RC (1985) Anti-thrombotic effect of curcumin. Thromb Res 40:413–417
Sugapriya D (2019) Augmented cytotoxic effects of paclitaxel by curcumin induced overexpression of folate receptor-α for enhanced targeted drug delivery in HeLa cells. Phytomedicine 56:279–285
Sumpter K (2005) Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 92(11):1976–1983
Sung YK, Hwang SY, Park MK, Farooq M, Han IS, Bae HI, Kim JC, Kim M (2003) Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 94:259–262
Suryanarayana P, Krishnaswamy K, Reddy GB (2003) Effect of curcumin on galactose-induced cataractogenesis in rats. Mol Vis 9:223–230
Syng-Ai C, Kumari L, Khar A (2004) Effect of curcumin on normal and tumour cells: role of glutathione and bcl-2. Mol Cancer Ther 3:1101–1108
Tang D, Zhang S, Shi X et al (2019) Combination of Astragali polysaccharide and curcumin improves the morphological structure of tumour vessels and induces tumour vascular normalization to inhibit the growth of hepatocellular carcinoma. Int Cancer Therapies 18(1):1–8
Trush MA, Twerdok LE, Esterline RL (1990) Comparison of oxidant activities and the activation of benzo(a)pyrene-7, 8-dihydrodiol by polymorphonuclear leucocytes from human, rat and mouse. Xenobiotica 20:925–932
Vajragupta O, Boonchoong P, Watanabe H, Tohda M, Kummasud N, Sumanont Y (2003) Manganese complexes of curcumin and its derivatives: evaluation for the radical scavenging ability and neuroprotective activity. Free Radic Biol Med 35:1632–1644
Vander Broek R, Snow GE, Chen Z, Van Waes C (2014) Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kB signalling. Oral Oncol 50:930–941
Vietor NO, George BJ (2012) Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent. J Oncol Pharm Pract 18(3):355–359
Vogel H, Pelletier J (1815) Curcumin –biological and medicinal properties. J de Pharmacie, 1: 289
Wang M, Löwik DW, Miller AD, Thanou M (2009) Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles. Bioconjug Chem 20(1):32–40
Wang C, Liu XQ, Hou JS, Wang JN, Huang HZ (2016) Molecular mechanisms of chemoresistance in oral cancer. Chin J Dent Res 19:25–23
Watt M (1995) Essential oils. Their lack of skin absorption but effectiveness via inhalation. AromatThymes 3(2):11–13
Westermarck J, Kahari VM (1999) Regulation of matrix metalloproteinase expression in tumour invasion. FASEB J 13:781–792
Wu L, Guo L, Liang Y et al (2015) Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signalling pathway. Oncol Rep 34:3311–3317
Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing effects of ERK and JNK–p38 MAP kinases on apoptosis. Science 270:1326–1331
Xu YX, Pindolia KR, Janakiraman N et al (1997) Curcumin, a compound with anti-inflammatory and anti-oxidant properties, down-regulates chemokine expression in bone marrow stromal cells. Exp Hematol 2(5):413–422
Xu G, Chen Y, Shan R, Chen L (2018) Transferrin and tocopheryl-polyethylene glycol-succinate dual ligands decorated cisplatin loaded nano-sized system for the treatment of lung cancer. Biomed Pharmacother 99:354–362
Xue X, Yu JL, Sun DQ, Kong F, Qu XJ, Zou W, Wu J, Wang RM (2014) Curcumin induces apoptosis in SGC-7901 gastric adenocarcinoma cells via regulation of mitochondrial signalling pathways. Asian Pac J Cancer Prev 15:3987–3992
Yamaguchi M, Moore TW, Sun A et al (2012) Novel curcumin analogue UBS109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-kappa B inhibition. Integrbiol 4(8):905–913
Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar APN (2009) Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol 2(4):321–328
Yu Y, Kanwar SS, Patel BB, Oh PS, Nautiyal J, Sarkar FH, Majumdar APN (2012) MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Carcinogenesis 33(1):68–76
Yu Y, Sarkar FH, Majumdar APN (2013) Down-regulation of miR-21 induces differentiation of chemoresistant colon cancer cells and enhances susceptibility to therapeutic regimens. Transl Oncol 6(2):180–186
Zangui M, Atkin SL, Majeed M, Sahebkar A (2019) Current evidence and future perspectives for curcumin and its analogues as promising adjuncts to oxaliplatin: state of the art. Pharmacol Res 141:342–356
Zhan Y, Chen Y, Liu R, Zhang H, Zhang Y (2014) Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signalling. Arch Pharm Res 37:1086–1095
Zhang F, Altorki NK, Mestre JR, Dannenberg AJ (1999) Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 20:445–451
Zhang BY, Shi YQ, Chen X et al (2013) Protective effect of curcumin against formaldehyde-induced genotoxicity in A549 Cell Lines. J Appl Toxicol 33:1468–1473
Zhang YP, Li YQ, Lv YT, Wang JM (2015) Effect of curcumin on the proliferation, apoptosis, migration, and invasion of human melanoma A375 cells. Genet Mol Res 14:1056–1067
Zhang S, Guan J, Sun M, Zhang D, Zhang H, Sun B, Guo W, Lin B, Wang Y, He Z, Luo C, Sun J (2017) Self-delivering prodrug-nano assemblies fabricated by disulphide bond bridged oleate prodrug of docetaxel for breast cancer therapy. Drug Deliv 24(1):1460–1469
Zhang W, Shi H, Chen C, Ren K, Xu Y, Liu X, He L (2018) Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop. Phytomedicine 48:51–61
Zhao G, Han X, Zheng S et al (2016) Curcumin induces autophagy, inhibits proliferation and invasion by downregulating AKT/mTOR signalling pathway in human melanoma cells. Oncol Rep 35:1065–1074